HEALTHCARE PROFESSIONAL RESOURCE CENTER — This site is intended for U.S. Healthcare Professionals only
close

Welcome to the PANCREAZE Advantage Healthcare Professional Resource Center

We are ready to assist you

Fast, convenient access to information and services to help you treat the Exocrine Pancreatic Insufficiency (EPI) patients you see in your practice. VIVUS is committed to helping ensure access to PANCREAZE. Patients may pay as little as $0.*

Order samples, request materials or a rep call

Download product information and patient materials

Download the PANCREAZE Dosing Assistant app

Your all-access account will connect you to a range of services. Please note that this website is intended for US Healthcare Professionals. Before beginning the registration process, make sure to gather your practice address and license information — you’ll need them when creating your account.

   
Already registered? Log In
 

* Eligible patients may pay as little as $0 on their co-pay for their PANCREAZE prescription with a maximum benefit of up to $100 per prescription fill (30-day supply) per month.

Important Safety Information

Fibrosing colonopathy is associated with high-dose use of pancreatic enzyme replacement. Exercise caution when doses of PANCREAZE (pancrelipase) exceed 2,500 lipase units/kg body weight per meal (or greater than 10,000 lipase units/kg body weight per day).

Hyperuricemia may develop. Consider monitoring uric acid levels in patients with hyperuricemia, gout, or renal impairment.

To avoid irritation of oral mucosa, do not chew PANCREAZE or retain in the mouth.

There is theoretical risk of viral transmission with all pancreatic enzyme products including PANCREAZE.

Exercise caution when administering pancrelipase to a patient with a known allergy to proteins of porcine origin.

Most common adverse reactions (≥ 10%) are: abdominal pain, flatulence, diarrhea, abnormal feces, and fatigue.

Additional Important Safety Information

PANCREAZE is not interchangeable with any other pancrelipase products.

Dosing should not exceed the recommended maximum dosage set forth by the Cystic Fibrosis Foundation Consensus Conferences Guidelines.

Indication

PANCREAZE is indicated for the treatment of exocrine pancreatic insufficiency due to cystic fibrosis or other conditions.

Please click here for the PANCREAZE Medication Guide and Full Prescribing Information.

 
References: 1. VIVUS, Inc. PANCREAZE®: Highlights of prescribing information. 2010.

Important Safety Information

Fibrosing colonopathy is associated with high-dose use of pancreatic enzyme replacement. Exercise caution when doses of PANCREAZE (pancrelipase) exceed 2,500 lipase units/kg body weight per meal (or greater than 10,000 lipase units/kg body weight per day).

Hyperuricemia may develop. Consider monitoring uric acid levels in patients with hyperuricemia, gout, or renal impairment.

VIEW ALL +